Director Willie Reed Sells Shares of Zoetis Inc (ZTS)
Zoetis Inc (NYSE:ZTS), a global leader in the discovery, development, manufacture, and commercialization of animal health medicines and vaccines, saw a recent insider transaction by Director Willie Reed. According to a SEC Filing, the insider sold 1,370 shares of the company on March 11, 2024.
Over the past year, the insider has sold a total of 1,370 shares and has not made any purchases of the company's stock. This latest transaction continues a trend observed over the past year, where there have been no insider buys and 17 insider sells for Zoetis Inc.
On the date of the insider's recent sale, shares of Zoetis Inc were trading at $182.68, valuing the company at a market cap of $83.034 billion. The price-earnings ratio of the company stands at 35.77, which is above the industry median of 22.92 but below the company's historical median price-earnings ratio.
The stock's price-to-GF-Value ratio is currently at 0.92, with a GF Value of $198.78, indicating that Zoetis Inc is Fairly Valued according to GuruFocus's valuation model. The GF Value is determined by considering historical trading multiples, a GuruFocus adjustment factor based on past returns and growth, and future business performance estimates from Morningstar analysts.
The insider trend image above reflects the recent selling activity by insiders at Zoetis Inc, providing investors with a visual representation of insider transactions over the past year.
The GF Value image provides an additional perspective on the stock's valuation, comparing the current share price to the intrinsic value estimate developed by GuruFocus.
For more detailed information on insider transactions and stock valuations, investors are encouraged to review the full SEC filings and explore the comprehensive data available on gurufocus.com.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
